GERAS Japan was an 18-month, prospective, multicenter, longitudinal, observational study conducted in 30 sites in different regions in Japan, designed to evaluate the costs and resource use associated with AD dementia for community-dwelling patients and their caregivers. Participants were enrolled from November 2016 to December 2017. Eligible patients were males and females aged ≥55 years old, who had received a diagnosis of probable AD according to the National Institute on Aging and Alzheimer’s Association and with a Mini-Mental State Examination (MMSE) score of 26 or less. At baseline, patients were stratified into groups based on AD severity (mild: MMSE 21-26, moderate: MMSE 15-20, and moderately severe/severe [MS/S]: MMSE < 15). Healthcare resource utilization and caregiver burden were assessed using the Resource Utilization in Dementia and Zarit “Caregiver” Burden Interview questionnaires, respectively. Total monthly societal costs were estimated using Japan-specific unit costs of services and products (patient direct healthcare use, patient social care use, and informal caregiving time). Overall, 553 patients (156 mild; 209 moderate; 188 MS/S) were enrolled with mean age 80.3 years, 73% female.
Manuscripts citing this dataset
- Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study. 2020. DOI: 3233/JAD-190811
- Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study. 2021. DOI: https://doi.org/10.1080/03007995.2021.1922369
- Increase in direct social care costs of Alzheimer's disease in Japan depending on dementia severity. 2021. DOI: https://doi.org/10.1080/03007995.2021.1922369
- Gender’s Effects to the Early Symptoms of Alzheimer’s Disease in 5 Asian Countries. DOI: https://doi.org/10.1177/1533317517698796
Request Access
Data access can be requested via AD Workbench FAIR portal here. Access requests are automatically approved and the dataset will be delivered to your workspace Inbox upon user-initiated transfer.
Data Use Agreement
More information on data access and use policies established by the trial sponsor can be found here.
Publishing results using this dataset?
The sponsor of this trial, Eli Lilly & Company, states their publication policy here.
Discuss
Post a question or thought about this dataset here.